Panacea Biotec Limited (PANACEABIO) AI Stock Analysis

• Market Cap: ₹20.31B
• Dividend Yield: N/A
• Average Volume (3M): 12.44K
• Price to Earnings (P/E): 144.8
• Beta (1Y): 1.51
• Revenue Growth: 9.78%
• EPS Growth: 50.78%
• Country: IN
• Employees: 1,936
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.65
• Shares Outstanding: 61,250,744
• 10 Day Avg. Volume: 14,140
• 30 Day Avg. Volume: 12,438
• PEG Ratio: -0.53
• Price to Book (P/B): 3.31
• Price to Sales (P/S): 4.94
• P/FCF Ratio: -35.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: ₹333.00 ▼(-7.11% Downside)
• Action: Reiterated Date: 01/09/26
• Date: Action: Reiterated 01/09/26

The score is primarily constrained by weak financial performance (ongoing losses, stagnant revenue, and negative operating/free cash flow). Technicals are a positive offset with an uptrend and bullish momentum, but valuation remains pressured due to a large negative P/E and no dividend yield data.

Positive Factors

Low leverage / strong equity ratio

Panacea’s very low debt-to-equity and high equity ratio provide durable financial flexibility: they reduce refinancing and bankruptcy risk, enable sustained investment in R&D and manufacturing capacity, and allow management to pursue tenders or partnerships without near-term leverage pressure.

Negative Factors

Negative operating and free cash flow

Persistent negative operating and free cash flow undermines internal funding for capex, working capital and R&D. Over a 2-6 month horizon this limits the company’s ability to scale manufacturing, meet tender collateral needs, or invest in commercialization without external financing despite low leverage.

Panacea Biotec Limited Business Overview & Revenue Model

Company Description

Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's prod...

Read more

Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's prod...

How the Company Makes Money

Panacea Biotec makes money primarily by selling pharmaceutical products and vaccine/biologics-related products and services across domestic and international markets. Key revenue streams typically include: (1) Product sales of finished-dose pharma...

Read more

Panacea Biotec makes money primarily by selling pharmaceutical products and vaccine/biologics-related products and services across domestic and international markets. Key revenue streams typically include: (1) Product sales of finished-dose pharma...

Panacea Biotec Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	6.04B	5.59B	5.52B	4.57B	6.59B	6.18B
Gross Profit	3.53B	3.60B	446.53M	1.78B	3.42B	4.13B
EBITDA	308.90M	307.40M	415.37M	563.65M	16.74B	865.18M
Net Income	-72.40M	-83.70M	-11.73M	-332.37M	10.78B	-1.48B
Balance Sheet
Total Assets	12.54B	12.90B	12.41B	12.71B	17.59B	11.78B
Cash, Cash Equivalents and Short-Term Investments	1.28B	1.79B	1.56B	2.13B	5.52B	954.44M
Total Debt	229.00M	222.10M	209.90M	202.19M	341.55M	8.20B
Total Liabilities	4.32B	4.59B	4.02B	4.31B	8.85B	14.09B
Stockholders Equity	8.26B	8.35B	8.42B	8.44B	8.77B	-2.29B
Cash Flow
Free Cash Flow	-260.70M	-776.80M	-778.18M	-4.63B	-1.21B	850.01M
Operating Cash Flow	-7.70M	-273.70M	-1.00M	-4.22B	-1.08B	1.07B
Investing Cash Flow	-153.90M	649.80M	102.27M	4.30B	12.83B	-476.79M
Financing Cash Flow	-23.00M	-26.60M	-28.08M	-183.73M	-11.76B	-471.10M

Panacea Biotec Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 358.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PANACEABIO, the sentiment is Positive. The current price of 358.5 is above the 20-day moving average (MA) of 327.61, above the 50-day MA of 342.18, and below the 200-day MA of 389.04, indicating a neutral trend. The MACD of -5.38 indicates Negative momentum. The RSI at 50.68 is Neutral, neither overbought nor oversold. The STOCH value of 66.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PANACEABIO.

Panacea Biotec Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	79 Outperform	₹775.43B	18.87	―	0.33%	7.33%	-3.79%
IPCALAB	73 Outperform	₹366.69B	27.58	―	0.28%	9.66%	25.79%
ALKEM	72 Outperform	₹627.33B	25.97	―	0.80%	9.32%	11.25%
GLAXO	63 Neutral	₹398.91B	35.44	―	2.16%	4.17%	41.51%
GLENMARK	53 Neutral	₹613.60B	35.61	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PANACEABIO	51 Neutral	₹20.31B	144.78	―	―	9.78%	50.78%